MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company’s participation in several upcoming conferences:

Event: Chardan’s In Vivo Gene Therapy and Gene Editing Summit
Panel Title: Gene Therapy and Gene Editing to the Retina
Panel Participant: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies
Date: Monday, March 18, 2019
Time: 5:05 – 6:05 pm ET
Location: Miami, Florida

Event: Retina World Congress Unplugged
Panel Title: Cell and Gene Therapy
Panel Moderator: Pravin Dugel, M.D., managing partner of Retinal Consultants of Arizona and clinical professor at the Department of Ophthalmology at the Keck School of Medicine, University of Southern California
Panel Participant: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies
Date: Thursday, March 21, 2019
Time: 10:07 – 10:34 am ET
Location: Fort Lauderdale, FL

Event:  2019 Cell & Gene Meeting on the Mediterranean
Presentation by: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies
Date:   April 22 – 24, 2019
Time:   1:35 pm CET
Location: Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, Spain
Webcast: http://www.meetingonthemed.com/webcast

About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. As a leader in ophthalmic gene therapy, Adverum has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.

Investor and Media Inquiries: 
Amy Figueroa, CFA
Investor Relations Consultant
afigueroa@adverum.com
650-823-2704

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.